Frequently asked questions about bone regeneration

Bone regeneration is the regrowth of bone tissue, harnessing the skeleton's own remodelling machinery. Bone is remodelled throughout life: osteoclasts resorb old bone and osteoblasts deposit new bone in its place. Regeneration research looks for ways to support that formation side when a defect or fracture is too large for natural healing to bridge.

Osteoclasts resorb bone: they attach to its surface and dissolve the mineral and digest the matrix with acid and enzymes. Osteoblasts build bone: they synthesise the collagen-rich matrix and drive its mineralisation with hydroxyapatite. Healthy bone mass is the balance between the two. Background: osteoblasts · osteoclasts.

BMPs are growth factors of the TGF-beta superfamily that induce the formation of bone and cartilage. Marshall Urist published the underlying discovery in Science in 1965; recombinant BMP-2 and BMP-7 are FDA-approved for some orthopaedic uses such as spinal fusions and certain nonunions. Background.

Yes — teriparatide (Forteo), a recombinant fragment of parathyroid hormone consisting of its first 34 amino acids (PTH 1-34). Approved by the FDA in 2002, intermittent dosing acts as an anabolic agent, stimulating osteoblasts and new bone formation in some forms of osteoporosis. Background.

In stages: a hematoma forms at the break, a soft callus bridges the gap, a hard callus mineralises that bridge, and remodelling then reshapes the bone over months to years. Unlike most tissues, bone can repair without a scar. Background.

Short amino-acid sequences designed to engage bone-formation signalling — for example motifs derived from BMP-2 or parathyroid hormone. The field is active and largely preclinical: peptides delivered from hydrogels, scaffolds and 3D-printed matrices. Most candidates are investigational; none described on this site is an approved therapy.

OsteoFast is Panacea Bio Chem's research record on bone regeneration and osteogenic peptides: a forward-looking perspective on designing, synthesising and preserving peptides that could engage bone-formation signalling. It is Panacea's research programme — the house's peptide design, synthesis and preservation competencies directed at bone-formation signalling.

No. This site is an educational research perspective. External science is cited to public sources; Panacea's own programme is labelled as in-house work. Nothing here is medical advice, and no content here is an instruction about any treatment.